Aker BioMarine has joined a partnership with Trofi Nutritionals to develop medical foods products using its product Lysoveta. This specific product contains essential nutrients.
Firstly, the krill-harvesting company will license Lysoveta to Trofi. In turn, it will conduct clinical trials for the development and commercialization of certain products.
Subsequently, the first trial is expected to be launched in 2024. The agreement also includes associated royalties on sales and relevant intellectual property rights and supply.
According to Aker BioMarine, the developed products will target Alzheimer's disease, male infertility and gestational diabetes. Also, it will include prenatal supplements in the US.
On the other hand, the United States Patent Trial and Appeal Board (PTAB) has just rejected a challenge against Aker BioMarine's patent US10,010,567B2. The company shares were up nearly 2% on Wednesday's close.
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. The company develops krill-based ingredients for pharmaceutical, nutraceutical (Superba®), aquaculture(QRILL®Aqua), and animal feed applications (QRILL®Pet). Including INVI™, a highly concentrated protein isolate, and LYSOVETA™, a targeted transporter of EPA and DHA from krill.
Founded in 2021, Trofi Nutritionals is an early-stage pioneer in next-generation nutritional solutions designed to support a range of health needs from managing chronic conditions to achieving wellness goals. Our team shares a passion for optimizing personal health through the power of nutrition.
